导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 19.90% | 380/4345 |
| 近一周 | 2.22% | 124/4962 |
| 近一月 | -5.89% | 3574/4922 |
| 近一季 | -7.89% | 2742/4747 |
| 近半年 | 16.50% | 323/4477 |
| 近一年 | 18.92% | 569/4016 |
| 近两年 | 145.43% | 256/2712 |
| 近三年 | 81.18% | 202/2054 |
| 成立以来 | -1.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.61% 4166/4961 |
74.89% 215/5312 |
- - |
- - |
| 2025 | 35.87% 968/4813 |
3.21% 1150/3635 |
-1.74% 3260/4076 |
48.66% 366/4524 |
-9.88% 4108/4813 |
| 2024 | 15.85% 872/3463 |
-10.56% 2350/2808 |
-6.47% 1961/3014 |
22.28% 488/3129 |
13.25% 155/3463 |
| 2023 | -11.25% 1384/2656 |
12.14% 315/2280 |
-6.77% 1702/2385 |
-11.47% 2067/2515 |
-4.11% 875/2655 |
| 2022 | -31.26% 1652/2207 |
-21.81% 1654/1919 |
1.51% 1464/2016 |
-15.07% 1204/2113 |
1.97% 1074/2208 |
| 2021 | 1.06% 693/1822 |
-10.50% 1116/1255 |
27.51% 61/1330 |
-13.58% 1350/1466 |
2.48% 582/1822 |
| 2020 | - - |
- - |
- - |
- - |
-0.89% 1088/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银上证科创50成份ETF VS. 长安沪深300非周期A(740101) |